Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

ved a single treatment in both legs of either placebo (12 subjects) or SB-509 (12 subjects who received 60 mg total dose, 30 mg per leg). All of the subjects completed 6-month follow-up testing. SB-509 was well tolerated and no drug-related severe adverse events were observed. Clinically relevant and statistically significant improvements were seen in neurologic examination using the Neurological Impairment Score - Lower Limbs (NIS-LL) and quantitative sensory testing (QST) which quantifies perception of vibration. In addition, there was a trend towards improvement in nerve conduction velocity (NCV), a measure of the ability of a nerve to transmit an applied electrical signal, in both sensory and motor nerves.

Specifically, improvement in neurologic evaluation by NIS-LL in SB-509-treated subjects was measured as a statistically significant, clinically relevant improvement of 1.9 point change from baseline levels compared to a 0.7 point worsening in the placebo group (a delta in NIS-LL of 2.6, p=0.043). In addition, there was a 25.3% improvement in detection of mechanical sensation compared to baseline, as measured by QST testing, in SB-509-treated patients compared to a 5.1% worsening in the placebo group (a delta in QST of 30.4%, p=0.02). The mean improvement in sensory (sural) NCV measurements 180 days post treatment was 1.2 Meters/sec with SB-509 treatment compared to -0.4 Meters/sec with placebo (a delta in NCV of 1.6 Meters/sec). The mean sum of improvement of all lower extremity motor NCV measurements 180 days post treatment was 0.8 Meters/sec with SB-509 treatment compared to -0.9 Meters/sec with placebo (a delta in NCV of 1.7 Meters/sec).

While the primary end-point of Sangamo's Phase 1b study (SB-509-401) was safety, data were also collected that were designed to measure changes in neurological health. Quantitative sensory testing (QST) using the Vibratron II is used as a method of assessing a subject's change in vibration sensitivity. Direct
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014   Aratana Therapeutics, ... biopharmaceutical company focused on the licensing, development and ... announced positive results from its pivotal field study ... treating pain in dogs with osteoarthritis.  In the ... assessment scores that were statistically significant compared to ...
(Date:12/17/2014)... 17, 2014 Los beneficios y ... alto nivel de gasto en investigación y desarrollo   ... el 30 de septiembre de 2014) ZEISS aumentó sus ... de euros (año anterior: 4.190 millones de euros) a ... ganancias (EBIT) crecieron un 14 por ciento, a 360 ...
(Date:12/17/2014)... , Dec. 17, 2014 With ... (MRI), the MRI market is seeing new growth, ... breast MRI scans account for the majority of ... higher resolution of images, which are creating opportunities for ... (MRI) market is growing at a rate of ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
... WASHINGTON, Dec. 15, 2010 Control Risks , one ... RiskMap 2011 – its annual review and forecast of ... a rating of political and security risk in 173 countries. ... increasing national self interest, both politically and economically, as the ...
... Dec. 15, 2010 GENTAG, Inc. and its partners ... platform for consumer cell phones. The technology, based on ... allergens and even certain types of cancers. ... for diseases and make diagnostics more accessible and affordable ...
Cached Medicine Technology:Control Risks Forecasts New Reality for Business in 2011 Brought by Emerging Markets, Legislation 2Cell Phones Are Now Personal Diagnostic Tools That Can Monitor Fertility, Pathogens, AIDS, Drugs, and Allergens 2
(Date:12/19/2014)... From November 24, 2014, Siddhi Yoga started ... in its Goa retreat . This is the third ... from November to March, Siddhi Yoga will organize four yoga ... The Goa training sessions will conclude in March 2015. ... the 10th intake is also a 200 YTT ...
(Date:12/19/2014)... The Hermitage Club at Haystack Mountain, ... Deerfield Valley, announced today that it has unveiled its ... , Three time Grammy Award Winner Kenny Loggins ... by a trail naming ceremony. Hermitage Club Founder, President ... Alright” the theme song for the movie soundtrack to ...
(Date:12/19/2014)... Randy Dotinga HealthDay ... -- Common painkillers, including ibuprofen, might slightly reduce your ... say. Use of ibuprofen (Advil, Motrin) and naproxen ... skin cancer by 15 percent, the researchers concluded after ... usually caused by sun exposure. These ...
(Date:12/17/2014)... Nwe is the co-author of a new weight loss book ... the Ace Medical Weight Loss Center in Rock Hill, SC. ... the industry of weight loss, and how several fad diets ... television shows, however, she says the topic of obesity is ... basic laughs, which she believes impacts whether Americans view it ...
(Date:12/17/2014)... December 17, 2014 In its comprehensive ... and its Argus Claim Review division have recently identified ... most common ways savings are achieved on behalf of ... millions of dollars in savings to Argus each year, ... , As explained by Tom Doney, Cypress president and ...
Breaking Medicine News(10 mins):Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2
... tumor which is found resistant to most of the ... The main causative agents for the development of Malignant ... virus 40 (SV40) is also found to be a ... people with malignant mesothelioma have worked or lived in ...
... children sustain at home can be of a grave nature ... result in deaths. ,Researchers at Cincinnati Children's Hospital Medical Center ... the journal Pediatrics// said that preventable injuries sustained at home ... They have studied the results taken from the National Vital ...
... genetic expressions by silencing some expressions of the gene.// ... and health conditions., ,Researchers at UT Southwestern Medical ... produce a drug for the treatment or cure of ... the online edition of the journal Nature Chemical Biology, ...
... and diligence in Britain of Indian origin hit headlines after ... the UK is well known for its long waiting lists ... a routine operation. This has brought NHS under criticism. ... had other ideas on how to deal with the waiting ...
... be easier to diagnose strokes affecting the left-brain than ... issue of The Lancet.// ,The authors state that ... symptoms of right-brain stroke. ,Cerebrovascular events are frequently ... of the brain the lesion occurs. People with events ...
... a recent study published for the first time, researchers ... oxidized phospholipids and the risk of coronary artery disease ... those of Lp(a) lipoprotein, the researchers suggest that that ... may be partly mediated by the proinflammatory oxidized phospholipids ...
Cached Medicine News:Health News:Malignant Mesothelioma – A New Genetic Revelatio 2Health News:Malignant Mesothelioma – A New Genetic Revelatio 3Health News:Indian Surgeon Conducts 70 Surgeries During His Holidays In England 2Health News:Stroke In The Right-Brain Can Remain Undiagnosed 2Health News:The Link Between Oxidized Phospholipids And Coronary Artery Disease 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: